Investment
Features
FeesSafety
Academy
More
Pluang+

Compare First Trust NASDAQ Cybersecurity ETF (CIBR) vs Eli Lilly And Co (LLY) Price & Performance

First Trust NASDAQ Cybersecurity ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

First Trust NASDAQ Cybersecurity ETF vs Eli Lilly And Co — how do they compare? First Trust NASDAQ Cybersecurity ETF trades at $100.01, while Eli Lilly And Co trades at $1,214.88 (market cap $1.10T). The key difference: Eli Lilly And Co pays a 0.56% dividend while First Trust NASDAQ Cybersecurity ETF pays none. Which is the better fit depends on your goals.

CIBRLLY
52-Week High
$100.60$1.24K
52-Week Low
$60.74$635.22
Market Cap
$1.10T
Sector
Health
Enterprise Value
$1.14T
Dividend Yield
0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

First Trust NASDAQ Cybersecurity ETF

CIBR, the First Trust Nasdaq Cybersecurity ETF, trades at $97.85, up 1.51% on the day, with a bullish technical signal from moving averages. The ETF has shown strong performance, reportedly outperforming the S&P 500 by three to one year-to-date as of June 5, 2026 (24/7 Wall Street). Recent news highlights institutional activity, including Bank of America reducing its stake while First Trust Advisors increased its position.

The outlook for CIBR is positive, driven by growing cybersecurity spending exceeding $300 billion in 2026 and AI-driven demand. Risks include high concentration in tech stocks and market volatility. Analyst sentiment is optimistic, with upgrades citing reasonable valuations and secular growth trends.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.

Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About First Trust NASDAQ Cybersecurity ETF

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index includes securities of companies classified as cyber security companies. The fund is non-diversified.

Read more on CIBR

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY